- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective
- Study aim: To describe the real-world use of, and outcomes from, early, mild-to-moderate COVID-19 treatments for the management of highest-risk patients from North-West London following the emergence of Omicron subvariants
- Number of participants enrolled: 5547
- Study enrolling from to
- Study includes follow-up for 1 month
- Standardisation: ICD-10, SNOMED CT
Study Data
- Adults
- General population
- Elderly
- Paediatric
- Primary care
- Community
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
- Molnupiravir
External Links
Other information
Funders:
- GSK
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to